Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27330132 | 0.81 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2CCHRNB4 | |
| SCHEMBL2246074 | 0.79 | PNMT (0.62) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL31561625 | 0.78 | CHRNB4 (0.44) | PNMTADRA2AADRA2BADRA2CCHRNB4 | |
| SCHEMBL28869614 | 0.74 | MAPT (0.50) | PNMTADRA2AMTNR1AADRA2BADRA2C | |
| SCHEMBL4108185 | 0.74 | MTNR1A (0.47) | PNMTADRA2AMTNR1AADRA2BADRA2C | |
| SCHEMBL3029057 | 0.73 | CHRNB4 (0.51) | PNMTADRA2ACHRNB4CHRNA3 | |
| SCHEMBL1011267 | 0.73 | CHRNB4 (0.51) | PNMTADRA2ACHRNB4CHRNA3 | |
| SCHEMBL1011265 | 0.73 | CHRNB4 (0.51) | PNMTADRA2ACHRNB4CHRNA3 | |
| SCHEMBL3033668 | 0.73 | CHRNB4 (0.51) | PNMTADRA2ACHRNB4CHRNA3 | |
| SCHEMBL5228137 | 0.71 | MTNR1A (0.67) | MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007139998-A2 | SYNTHESIS OF A COMPOUND WHICH IS A SUITABLE INTERMEDIATE IN THE SYNTHESIS OF OXINDOLEDIOXANE DERIVATIVES | WYETH (US) | 2007-12-06 | — | — | WO | disclosed |